Fibrotic microtissue array to predict anti-fibrosis drug efficacy
A bottleneck in developing new anti-fibrosis therapies is the absence of suitable in vitro models that recapitulate key features of fibrogenesis. Here the authors develop a tissue-on-a-chip model of lung fibrosis and test the therapeutic efficacy of two recent FDA-approved drugs.
Main Authors: | Mohammadnabi Asmani, Sanjana Velumani, Yan Li, Nicole Wawrzyniak, Isaac Hsia, Zhaowei Chen, Boris Hinz, Ruogang Zhao |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2018-05-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-018-04336-z |
Similar Items
-
Microclot array elastometry for integrated measurement of thrombus formation and clot biomechanics under fluid shear
by: Zhaowei Chen, et al.
Published: (2019-05-01) -
Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity
by: Seidai Sato, et al.
Published: (2017-09-01) -
Activated Cardiac Fibroblasts Control Contraction of Human Fibrotic Cardiac Microtissues by a β-Adrenoreceptor-Dependent Mechanism
by: Przemysław Błyszczuk, et al.
Published: (2020-05-01) -
Anti-fibrotic effects of valproic acid in experimental peritoneal fibrosis.
by: Elerson C Costalonga, et al.
Published: (2017-01-01) -
Endostatin in fibrosis and as a potential candidate of anti-fibrotic therapy
by: Zequn Zhang, et al.
Published: (2021-01-01)